Evgen is developing Sulforadex, a synthetic pharmaceutical based on sulforaphane, a compound produced after eating broccoli and other brassica vegetables with documented cancer-protective benefits. The company is led by CEO Dr Stephen Franklin and is based in Liverpool, UK. Evgen intends to use new funding to begin clinical trials of Sulforadex, initially targeting early‑stage “indolent” prostate cancer. Management says the molecule has potential applications across multiple cancers. The company has attracted backing from existing investors and government support to advance its program. The article discloses the recent funding and grant but provides no operating metrics. Evgen Limited is a Liverpool, UK-based pharmaceutical company focused on commercializing the clinical potential of sulforaphane. Founded in 2008 by CEO Dr Stephen Franklin, the company is developing Sulforadex®, a patented pharmaceutical composition aimed at preventing and treating prostate cancer and other cancers. Evgen intends to use the funding to complete the pre-clinical development of Sulforadex®. The company raised its first "significant" venture capital investment in a Series A round backed by the North West Fund for Biomedical (managed by SPARK Impact), EV Group’s Rising Stars Growth Fund, and a number of private individuals. A second closing of the round is expected later in the year.

Total raised

$1M

Funding rounds

3

Latest round

Grant

Latest activity

Jul 2012